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Background: Patients with poorly controlled type 2 diabetes (T2D) experience increased morbidity, increased mortality, and
higher cost of care. Self-monitoring of blood glucose (SMBG) is a critical component of diabetes self-management with established
diabetes outcome benefits. Technological advancements in blood glucose meters, including cellular-connected devices that
automatically upload SMBG data to secure cloud-based databases, allow for improved sharing and monitoring of SMBG data.
Real-time monitoring of SMBG data presents opportunities to provide timely support to patients that is responsive to abnormal
SMBG recordings. Such diabetes remote monitoring programs can provide patients with poorly controlled T2D additional support
needed to improve critical outcomes.
Objective: To evaluate 6 months of a diabetes remote monitoring program facilitated by cellular-connected glucose meter,
access to a diabetes coach, and support responsive to abnormal blood glucose recordings greater than 400 mg/dL or below 50
mg/dL in adults with poorly controlled T2D.
Methods: Patients (N=119) receiving care at a diabetes center of excellence participated in a two-arm, 12-month randomized
crossover study. The intervention included a cellular-connected glucose meter and phone-based diabetes coaching provided by
Livongo Health. The coach answered questions, assisted in goal setting, and provided support in response to abnormal glucose
levels. One group received the intervention for 6 months before returning to usual care (IV/UC). The other group received usual
care before enrolling in the intervention (UC/IV) for 6 months. Change in hemoglobin A1c (HbA1c) was the primary outcome,
and change in treatment satisfaction was the secondary outcome.
Results: Improvements in mean HbA1c were seen in both groups during the first 6 months (IV/UC −1.1%, SD 1.5 vs UC/IV
−0.8%, SD 1.5; P<.001). After crossover, there was no significant change in HbA1c in IV/UC (mean HbA1c change +0.2, SD 1.7,
P=.41); however, those in UC/IV showed further improvement (mean HbA1c change −0.4%, SD 1.0, P=.008). A mixed-effects
model showed no significant treatment effect (IV vs UC) over 12 months (P=.06). However, participants with higher baseline
HbA1c and those in the first time period experienced greater improvements in HbA1c. Both groups reported similar improvements
in treatment satisfaction throughout the study.
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Conclusions: Patients enrolled in the diabetes remote monitoring program intervention experienced improvements in HbA1c
and treatment satisfaction similar to usual care at a specialty diabetes center. Future studies on diabetes remote monitoring
programs should incorporate scheduled coaching components and involve family members and caregivers.
Trial Registration: ClinicalTrials.gov NCT03124043; https://clinicaltrials.gov/ct2/show/NCT03124043
(JMIR Diabetes 2021;6(1):e25574) doi: 10.2196/25574
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Introduction
Poorly controlled diabetes, as indicated by elevated hemoglobin
A1c (HbA1c), is associated with higher morbidity and mortality
[1], greater cost of treatment [2], and poorer adherence to
recommended self-management behaviors [3]. To improve
HbA1c, diabetes self-management support needs to be accessible,
responsive to varying patient health status, and effective in
improving self-management skills, knowledge, and engagement.
This is especially important for patients who struggle with
self-management or face barriers to accessing traditional
in-person services due to social determinants of health [4].
Integrated health care systems and payers, including commercial
health plans, are particularly interested in innovative approaches
to self-management support that address diabetes quality
measures while reducing the overall cost of care [5].
Consequently, various commercial products have been
developed to improve diabetes self-management, improve the
experience of care, and reduce overall costs.
Electronic remote patient monitoring is a common strategy for
many diabetes self-management applications available. This
generally involves the transmission of self-monitored blood
glucose readings to health care professionals and teams for
evaluation and feedback [6]. Such real-time provider access to
patient monitoring data presents an opportunity for care teams
to deliver timely, tailored support without in-person contact.
However, additional research targeting provider behavior with
consideration of reimbursement for time and effort is needed
to successfully integrate remote monitoring into routine care
[7]. A recent meta-analysis of 4 systematic reviews of
randomized controlled trials evaluating phone- and
internet-based monitoring found improvement in HbA1c levels
of −0.55% (95% CI −0.73 to −0.36) compared with usual care,
though with statistical heterogeneity [6]. Notably, only 14 of
25 randomized trials reported significant improvement over
usual care, with variability in what usual care support entails,
as well as study quality. Potentially, positive findings may
represent substandard care in comparison groups and may reflect
the lack of resources required to ensure adequate evaluation and
feedback is given to patients.
The Livongo for Diabetes Program is commercially available
for purchase for individual use or can be implemented through
a health organization or insurer. The program highlights the
integration of Certified Diabetes Educators (CDEs), also referred
to as Certified Diabetes Care and Education Specialists, who
can provide real-time feedback on glucose monitoring data,
including immediate responses to abnormal glucose excursions.
One prior observational study of over 4500 individuals with
diabetes using the Livongo for Diabetes Program found a
decrease in glucose levels outside of a 70-180 mg/dL range [8].
However, the study did not include a comparison group to
establish efficacy, and HbA1c was not assessed to understand
if there was less hypoglycemia, less hyperglycemia, or both.
The present study was a randomized controlled crossover trial
testing the efficacy of 6 months of participation in the Livongo
for Diabetes Program in patients with poorly controlled type 2
diabetes. The primary outcome of the trial was change in HbA1c,
with a secondary outcome of change in diabetes treatment
satisfaction. In this study, we hypothesized that patients would
experience greater improvements in HbA1c and treatment
satisfaction when enrolled in the intervention program compared
to usual care. Additionally, we explored engagement with the
program, including monitor use and receipt of CDE support.
Methods
Setting and Recruitment
Participants with type 2 diabetes were recruited at the University
of Massachusetts Medical Center Diabetes Center of Excellence
(DCOE) from April 1 to July 9, 2015. All patients at the DCOE
have both a primary care provider and a DCOE specialist
provider. Inclusion criteria included the ability to speak English,
a diagnosis of type 2 diabetes, and two consecutive HbA1c
recordings greater than 8.0% in the previous 12 months,
indicating poor glycemic control. Subjects were excluded if
they were cognitively impaired (as designated by their provider),
pregnant, or a prisoner. All human subjects research was
reviewed and approved by the University of Massachusetts
Medical School Institutional Review Board.
Research staff screened medical records of patients scheduled
for routine appointments to identify those meeting the HbA1c
criterion. The staff approached potentially eligible patients in
the clinical environment and privately screened for eligibility
if patients expressed interest. Patients were informed that they
would be given access to the Livongo for Diabetes Program for
a total of 6 months, either immediately or after a 6-month
waiting period, randomly determined. Interested and eligible
participants signed consent forms. Of 195 eligible subjects
approached for recruitment, 123 (63.1%) expressed interest in
participating, and 120 (61.5%) completed the informed consent
process and were randomized to treatment groups. One subject
failed to complete the baseline survey and was lost to follow-up
prior to enrollment in the intervention.
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The intervention included free enrollment in the Livongo for
Diabetes Program [9], the Livongo In Touch connected glucose
meter, and a 6-month supply of testing supplies. The Livongo
for Diabetes Program is accredited by the American Association
of Diabetes Educators (AADE) Diabetes Education
Accreditation Program and includes access to both scheduled
and in-the-moment CDE support via phone call or SMS text
messaging. At the time of the study, the Livongo for Diabetes
program was not available as a direct-to-consumer product but
was available to employees of several large companies.
The In Touch connected glucose meter is cellular-enabled,
allowing for automatic uploading of self-monitoring of blood
glucose (SMBG) recordings to a secure patient portal. Patients
were instructed to use the meter to test their blood glucose as
frequently as previously instructed by their providers. After
patients use the meter to test their glucose, the SMBG recording
is uploaded to the Livongo Smart Cloud. In this study, Livongo
transferred all SMBG data to the DCOE electronic health record
(EHR) system daily. The first time an uploaded blood glucose
recording was above 250 mg/dL and anytime it was above 400
mg/dL or below 50 mg/dL, the Livongo Smart Cloud would
notify the Livongo Care Team to perform outreach to the patient.
The Livongo Care Team of CDEs would contact participants
by their preferred communication method (either phone call or
text message) within 3 minutes of receiving an abnormal SMBG
notification from the Smart Cloud. When contact was made,
they would assess if the patient needed immediate medical
attention, troubleshoot reasons for the flagged SMBG recording,
and provide resources to improve self-management of diabetes.
If a participant needed immediate medical attention, the CDE
would direct them to call 911. If the intervention CDE believed
a participant was in need of additional support from their DCOE
care team, the CDE would contact the DCOE directly to request
follow-up with the patient. Documentation of all encounters
between intervention CDEs and participants was sent to the
DCOE weekly to be entered into the EHR (Figure 1 for
intervention components and flow of data). While the SMBG
and CDE encounter data were available to the DCOE providers,
the study did not target DCOE provider behavior (eg, by
encouraging the providers to review or use the intervention data
available in the EHR).
Figure 1. Intervention components and flow of patient data. CDE: Certified Diabetes Educator; SMBG: self-monitoring of blood glucose.
Intervention participants were encouraged at enrollment and
during each CDE outreach to schedule follow-up coaching
sessions with the CDEs. Coaching sessions covered the AADE’s
7 self-care behaviors: healthy eating, being active, glucose
monitoring, taking medication, problem solving, reducing risks,
and health coping [10]. While intervention CDEs did not give
participants medical direction or make changes to their care
plans, they answered diabetes-specific questions on topics such
as nutrition and lifestyle changes and contacted the DCOE if
they believed the participant would benefit from additional
medical intervention.
Text-based messages sent to the participants through the meter
after each test were based on the AADE National Standards for
Diabetes Self-Management Education curriculum and included
feedback and diabetes self-management tips. Other features of
the meter included tagging SMBG recordings with contextual
information (before meal, after meal, neither, and how they
were feeling at the time of testing), an electronic logbook, and
a built-in physical activity tracker. The meter also allowed
participants to share SMBG data with their care providers or
family via text message, email, or fax. While Livongo now
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offers a mobile phone app to accompany the In Touch meter,
this app was not available at the time of the study.
Usual Care
Participants in the usual care group continued to receive
specialty care from DCOE and primary care providers. This
included the recommended quarterly appointments with their
DCOE care team and regular access to their providers through
phone calls or secure messaging through the patient portal.
Randomization
A randomization table was created prior to the start of
recruitment to equally allocate 120 participants to 2 treatment
groups. The first group received the intervention for 6 months
and then returned to usual care (IV/UC) for 6 months. The
second group received usual care for 6 months before enrolling
in the intervention (UC/IV) for 6 months. Study staff not
involved with recruitment created enrollment folders for each
participant based upon the randomization table. Study staff
responsible for recruitment were blinded to treatment group
designation from study enrollment during baseline questionnaire
administration. For participants randomized to receive the
intervention during the first time period, the last baseline survey
item asked if they would like to schedule a phone call with
research staff to walk through using the connected glucose meter
when they received it at home. Those interested were scheduled
for a tutorial approximately 7 days later, after confirmed delivery
of the intervention start-up package containing the connected
glucose meter and testing materials. A similar tutorial request
process occurred at the end of the 6-month survey for
participants receiving the intervention during the second time
period.
Data Collection
At study enrollment, participants had an HbA1c test drawn.
Participants were scheduled to return at 3, 6, 9, and 12 months
±1 week post–study enrollment for HbA1c testing. For
participants who did not return for their scheduled 6-month
(23/119, 19.3%) and 12-month (34/119, 28.6%) test, an HbA1c
recording from their closest clinical visit was extracted from
the EHR if it was within 3 months of the scheduled lab testing
date (49/57, 86% of total missing). For patients without an
available HbA1c in the EHR (8/57, 14% of total missing), change
in HbA1c was imputed with the mean of their treatment group
in mixed-effects modeling analyses.
Participants completed paper questionnaires at baseline, 6
months (prior to treatment crossover), and 12 months (study
completion). Participants were administered questionnaires at
the clinic and could finish them at home and mail them back,
if necessary. Data from the questionnaires were manually
entered by study staff using REDCap data capture tools [11].
Data on engagement with intervention, including number of
SMBG recordings, number of CDE contacts, and number of
CDE coaching sessions were collected by Livongo and securely
transferred to study staff for manual entry into the REDCap
project.
Primary and Secondary Outcomes
Changes in HbA1c during each time period were the primary
outcomes of this study. HbA1c change was evaluated by
comparing the mean changes in HbA1c while receiving the IV
compared to HbA1c change while receiving UC. This was done
for both the first treatment period and the second treatment
period. Overall impact of the intervention on the change in
HbA1c across both time periods was assessed in a mixed-effects
model.
Diabetes treatment satisfaction was chosen as a secondary
outcome because it is associated with positive diabetes
outcomes, including HbA1c [12]. To measure baseline
satisfaction with diabetes treatment, the Diabetes Treatment
Satisfaction Questionnaire (DTSQ) was completed. The DTSQ
is an 8-item measure with responses ranging from very satisfied
to very dissatisfied for a total scale score range of 0 to 36 [13].
To evaluate change in satisfaction attributable to the
intervention, the Diabetes Treatment Satisfaction Questionnaire
Change (DTSQc) was included in the 6-month and 12-month
questionnaires. The DTSQc is an 8-item measure that asks the
extent to which participants experienced change in satisfaction
over the course of the previous 6 months with responses ranging
from much less satisfied now (−3) to much more satisfied now
(+3) [14].
Sample Size Estimation
The primary outcome of this study was change in HbA1c. We
anticipated the distribution of change in HbA1c would
approximate a normal distribution, allowing for the use of a
standard t test to examine differences in mean HbA1c change
between treatment groups during each time period. Based on
previous interventions in this patient population [15,16], we
assumed a 1.0% difference in mean HbA1c change between
treatment groups and a 1.5 SD in HbA1c change for both groups,
requiring 48 participants per group for 90% power and a type
I error rate of .05. We assumed a 10% dropout, which required
53 participants per arm. A conservative approach targeted
recruitment of 60 participants per treatment group. Sample size
calculations were performed using the SAMPSI command in
Stata software, version 13.1 (StataCorp).
Analytic Plan
Bivariate comparisons of baseline characteristics between
treatment groups were conducted to evaluate success of
randomization. Baseline characteristics of the participants who
failed to return for the 6-month and 12-month follow-up
appointments were compared against those of participants who
completed follow-up visits by using independent samples
two-tailed t tests.
Primary outcome analyses involved independent samples
two-tailed t tests to examine differences in HbA1c change
between treatment groups during the first and second time
periods. Both intent-to-treat and completer analyses were
conducted. Participants were considered completers if they
returned for the 6-month and 12-month follow-up visits. To
account for the crossover design and multiple time points of the
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study, a random intercept mixed-effects model with a restricted
maximum likelihood estimator option of the mixed procedure
in SAS software, version 9.4 (SAS Institute), was performed to




Study participants (n=119) had mean baseline HbA1c of 10.1%
(SD 1.4). Age at enrollment ranged from 23 to 84 years old with
an average age of 56.7 years (SD 11.6). The study sample was
52.9% (63/119) women and 71.4% (85/119) white (Table 1).
Both groups were similar in terms of demographic
characteristics, insulin use, HbA1c, and treatment satisfaction.
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Table 1. Study participants’ characteristics.
P valueUC/IVb (n=60)IV/UCa (n=59)Characteristics
.5557.4 (12.1)56.1 (11.1)Age (years), mean (SD)








—0 (0)1 (2)Native/Alaskan American 
—6 (10)7 (12)More than 1 race 
—6 (10)5 (8)Not reported 
.81Ethnicity, n (%)
—9 (15)11 (19)Hispanic Latinx 
—48 (80)46 (78)Not Hispanic Latinx 
—3 (5)2 (3)Not reported 
.80Education, n (%)
—7 (12)9 (15)<High school grad 
—17 (28)18 (31)High school grad 
—5 (8)6 (10)Post–high school trade 
—16 (27)14 (24)1-3 years college 
—13 (22)11 (19)College grad 
—2 (3)1 (2)Not reported 





—6 (10)3 (5)Not reported 
.73Internet access, n (%)
—11 (18)9 (15)No 
—47 (78)50 (85)Yes 
—2 (3)0 (0)Not reported 




d %, mean (SD)
.2428.4 (5.2)29.6 (5.3)Treatment satisfaction [14], mean (SD)
aIV/UC: intervention for 6 months before usual care for 6 months.
bUC/IV: usual care for 6 months before intervention for 6 months.
cNot available.
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Of the 119 study participants, 97 (81.5%) returned for the
6-month HbA1c lab, and 92 (77.3%) completed the 6-month
follow-up survey (Figure 2). After treatment crossover, 86
(72.3%) participants returned for the 12-month HbA1c test, and
92 (77.3%) participants completed the 12-month follow-up
survey. HbA1c data from the nearest clinical appointment were
extracted for 19 of the 22 (86%) participants who did not return
for the 6-month HbA1c lab and 30 of the 33 (91%) participants
who did not return for the 12-month HbA1c lab. HbA1c values
for the remaining participants with missing values at 6 months
(n=3) and 12 months (n=3) were set to their group’s mean value
so that the final analytic sample included follow-up HbA1c data
for all 119 participants at the 6-month and 12-month time points.
Figure 2. Participant CONSORT (Consolidated Standards of Reporting Trials) diagram. HbA1c: hemoglobin A1c.
Engagement With Intervention
Among participants randomized to receive the intervention first
(IV/UC, n=60), 1 (2%) did not enroll in the intervention
program, and 6 (10%) never used the intervention meter. Of the
60 participants randomized to receive the intervention in the
second period (UC/IV), 11 (18%) did not complete the 6-month
follow-up visit and subsequently failed to enroll in the
intervention. Of those participants who enrolled in the
intervention in the second period (n=49), 8 (16%) never used
the meter.
Among all participants who used the intervention meter during
either time period (n=94), the average number of SMBG
recordings per participant over the 6-month intervention period
was 220 (SD 165, range: 2-817). For these participants, 73
(78%) were contacted by an intervention CDE at least once in
response to a high or low SMBG recording outside of range.
Over the course of the entire study, 400 support contacts were
attempted by intervention CDEs, with 295 (73.8%) successful
contacts, defined as reaching the patient (phone call) or receiving
a reply (text message). Of these, 183 (62.0%) were by phone,
and 112 (38.0%) were by SMS text messaging. Among the 73
participants contacted in response to a flagged SMBG, 11 (15%)
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scheduled at least one follow-up coaching session with an
intervention CDE. Among those who completed a coaching
session with an intervention CDE, the average number of
coaching sessions was 2.5 (SD 1.5) with a range from 1 to 5
total coaching sessions.
Change in HbA1c
Similar rates of HbA1c change were seen between both groups
after 6 months (t114=1.06, P=.29), with the intervention
improving mean HbA1c by 1.1% (SD 1.5; P<.001) and usual
care by 0.8% (SD 1.5; P<.001) (Table 2). After crossover, those
returning to usual care (IV/UC) did not experience significant
change in mean HbA1c (P=.41), while those who began receiving
the intervention (UC/IV, n=39) had additional improvement in
mean HbA1c by 0.4% (SD 1.0; P=.008) (Figure 3). The
difference in mean HbA1c change during the second time period
between groups was not statistically significant in intent-to-treat
analyses (P=.09) but was significant among the participants
who completed the final study visit (P=.03) (Table 2).








.29−0.8 (1.5)60−1.1 (1.5)56∆ HbA1c % from baseline
(ITTe)
 





.07−0.4 (1.5)60+0.2 (1.7)56∆ HbA1c % from 6-month
(ITT)
 




aIV/UC: intervention for 6 months before usual care for 6 months.
bUC/IV: usual care for 6 months before intervention for 6 months.
cHbA1c: hemoglobin A1c.
dDTSQ: Diabetes Treatment Satisfaction Questionnaire.
eITT: intent-to-treat.
fDTSQc: Diabetes Treatment Satisfaction Questionnaire Change.
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Figure 3. Mean HbA1c % at 0, 6, and 12 months, by group*. HbA1c: hemoglobin A1c; IV: intervention; UC: usual care.
The mixed-effects model (Table 3) showed a nonsignificant
difference in HbA1c improvement of 0.4% between the
intervention and usual care treatment conditions (P=.06). The
model also showed significant effects of baseline HbA1c (P=.03)
and time period (P<.001). Participants with higher baseline
HbA1c saw greater HbA1c improvement across the whole study,
and there was greater HbA1c improvement in the first period
compared to the second period.
Table 3. Results of crossover (mixed-effects model) analysis of HbA1c change.
P valueSDHbA1c
a % change estimateVariable
.030.07−0.15Baseline HbA1c
.060.19−0.37Treatment (IVb vs UCc)





Change in Diabetes Treatment Satisfaction
Among participants completing the 6-month questionnaire
(n=96), those receiving the intervention reported a mean
improvement in treatment satisfaction of +12.9 (SD 5.6)
compared to +10.7 (SD 6.6) with usual care (P=.09). Among
those completing the final questionnaire (n=82), those who
returned to usual care in the second time period (IV/UC)
reported an improved mean treatment satisfaction change score
of +11.5 (SD 6.8) compared to +13.4 (SD 4.5) among




In this 12-month randomized crossover trial, we found that
patients enrolled in a diabetes remote monitoring program
experienced improvements in HbA1c and treatment satisfaction
similar to usual care at a specialty diabetes center. Our
mixed-effects model assessing HbA1c change over both 6-month
time periods estimated that HbA1c improvement produced by
the intervention was approximately 0.4% greater than that
produced by usual care, though not reaching statistical
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significance (P=.06). At the same time, we did not observe
differences in treatment satisfaction between the program and
usual care. Together, these findings provide additional evidence
regarding the expected outcomes of a commercial remote
monitoring program, which may be useful for health
organizations and insurers to consider in making decisions for
patient self-management support.
In the first 6 months, patients experienced improvement in
HbA1c, including those receiving usual care, who exhibited
improvement in mean HbA1c by −0.8%. This is a common
finding in comparable trials involving patients with uncontrolled
diabetes and may result from multiple factors. First,
improvement through usual care could be due to the Hawthorne
effect [17]. Participants received additional attention and
engaged frequently with research staff, they were called and
reminded to return quarterly for HbA1c testing, and they knew
they would receive the anticipated commercial intervention
after 6 months. Second, patients received specialized care
through the DCOE endocrinologists and may represent more
intensive blood glucose management than typically experienced
through the primary care setting. This and potential “spillover”
effects may have additionally narrowed differences observed
between treatment conditions. Finally, “regression to the mean”
may have contributed to improvements in all patients by
recruiting only those with higher baseline HbA1c levels to the
study.
Comparison With Prior Work
As in other studies, patients who missed follow-up visits for
data collection had higher baseline HbA1c levels. For these
individuals, it is not clear that commercial programs adequately
address the barriers to complex diabetes self-management
behaviors and social determinants of health, particularly with
remote CDE support. Program CDEs may not develop the same
relationships with patients as health care team members or
recognize cultural, regional, or other psychosocial issues that
may influence glycemia. Unfortunately, in many health care
settings these patients still tend to have high no-show rates for
appointments, worse diabetes-related health outcomes, lower
rates of SMBG testing, and greater medication nonadherence
[18-20].
Similar interventions involving SMBG and targeting patients
with poorly controlled diabetes have demonstrated improvement
in health outcomes for this increasingly prevalent and costly
patient population [15,16,21-27]. Unique to this intervention
was the in-the-moment, virtual support provided in response to
abnormal SMBG levels uploaded automatically by connected
glucose meters. By contacting patients immediately after their
blood glucose tests high or low, CDEs could offer timely support
when patients may need it most (eg, immediate hypoglycemia
treatment). The CDE could also take advantage of “teachable
moments” to provide diabetes education and self-management
training when there is greater attention [28]. During these
unplanned opportunities, patients can gain a better understanding
of why their blood glucose is outside of range and learn how
best to prevent it from happening again in the future.
While timely CDE outreach may be useful for some patients,
it could also prompt stress in those who may not want to be
contacted when SMBG levels are out of range. To address this
concern, participants could adjust the SMBG levels that would
trigger CDE contact; however, no participants requested to do
this during the study. This may be secondary to following a
“default” (status quo bias) [29] or may be due to a lack of
technological knowledge on how to fully operate the meter. As
a result, it remains possible that individuals will avoid
self-testing if they suspect their levels are more extreme to avoid
CDE involvement, especially if they exhibit more risk-seeking
behavior [30]. If true, it suggests that for future implementation,
this option should be emphasized upon initial training or
reassessed over time.
Similarly, we found that only a small proportion of participants
scheduled an individual coaching session with a program CDE.
Routine scheduled coaching sessions for all participants may
further enhance delivery of diabetes self-management education
and training in this population. Additionally, CDEs could contact
and counsel patients who have not recorded an SMBG level
over an extended period. Besides the CDEs, the program could
encourage greater involvement of a patient’s care team and
support system, including informal caregivers such as family
members. Providing caregivers with electronic access to a
patient’s SMBG recordings and tools to assist in disease
management may improve the quality of support they provide
and reduce their own caregiver burden. We did not investigate
the effects of this intervention on caregiver support and burden,
but this should be considered in a future study.
Strengths
There were several strengths in this study. We collected both
physiological (HbA1c) and patient-reported (diabetes treatment
satisfaction) outcomes. Prior study of the program only included
detection of glucose levels outside of range and excluded
treatment satisfaction [8]. Additionally, the randomized
controlled crossover study design allowed for both between-
and within-group comparisons. This provided a more
comprehensive evaluation by time period, treatment, and
sequence of treatment received. Finally, we built an application
programming interface to allow the transfer of SMBG and
CDE/patient interactions from the Livongo cloud-based system
to the clinic’s EHR. This allowed for the intervention data to
be accessible to the patients’ care teams between clinic
appointments.
Limitations
There are several limitations of this study to consider. The
intervention time period was relatively short (6 months) for a
group of patients with poorly controlled diabetes receiving care
at a specialty diabetes center. The limited exposure to the
intervention did not allow for evaluation of a sustained
intervention effect. In addition, as only patients receiving the
intervention had SMBG recordings regularly uploaded, we did
not compare frequency of blood glucose testing during
intervention compared to usual care. More research is needed
with longer durations of intervention treatment, as most studies
are 12 months or less [6], and in other patient populations, as
this study only focused on patients with poorly controlled
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diabetes and did not collect data on duration of diabetes at time
of enrollment. Second, data analyzed are from 2015 to 2016,
and the intervention program has made several adaptations since
study completion. Livongo has partnered with several companies
recently, including Dexcom and their continuous glucose
monitoring (CGM) devices and Fitbit with their physical activity
trackers. Furthermore, Livongo recently merged with Teladoc
Health, a leading telemedicine provider. Further study of
Livongo’s effect after incorporating CGM devices, wearable
devices with more telehealth human coaching activities and
advanced decision support, is needed. This is especially
important considering a very limited number of participants in
this study took advantage of a scheduled coaching session.
As well, while accessibility to virtual diabetes care support
programs like Livongo has increased recently, many patients
may continue to face barriers accessing or affording such
support. These access to care challenges limit the
generalizability of the study to only patients with access to such
programs. Additionally, this study did not target provider
behavior. SMBG data was uploaded to the EHR daily, but
optimizing the use of these data by the usual care team was not
part of the intervention. In regard to retention, several
participants failed to return for their 6-month visit (28%), with
those in the UC/IV group never receiving the intervention during
the second study time period. Lastly, there may have been
carryover of treatment effects for participants who received the
intervention first (IV/UC), especially considering the absence
of a washout period in the study design.
Conclusions
We found that patients with poorly controlled diabetes enrolled
in the commercial remote diabetes monitoring program
experienced improvements in HbA1c similar to when they
received usual care at a specialized diabetes center. Improved
treatment satisfaction was also reported by both groups
throughout the study. Further development targeting patient
engagement in the program and access to CDEs for diabetes
support could result in greater program impact, especially for
patients with limited access to specialized diabetes care. Future
interventions involving diabetes care monitoring programs and
connected technologies should consider including a structured
coaching component, proactively involving caregivers and
family members of patients, and investing in additional efforts
to engage patients who are more likely to miss scheduled study
activities and appointments. Better integration of diabetes remote
monitoring programs into routine clinical care must be
prioritized. This is necessary in order to achieve the full potential
benefit from similar interventions in the future. In addition,
cost-effectiveness needs to be investigated. This will be critical
in justifying the expense required to provide in-the-moment
support offered by the intervention.
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